INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.GeronGERN (market cap $0.532B)Geron is an extremely innovative biotech, willing to use the latest technologies and techniques (which are becoming more familiar as time progresses) to tackle the tough medical problems like organ replacement, cancer treatments, etc. Their primary lines of research and development are stem cells (organ replacement and nerve regeneration), telomerase (cancer treatments), and nucleus transfer (cloning). They have begun stem cell clinical trials for at least partially restoring nerve function in humans. The company has survived for years via avenues like dilution and licensing. I like what they are doing and am impressed with their awareness of ethics, legalities, and public opinion while also being flexible and driving towards sustainability. I recall that they've done some research outside the US where it was better accepted.I will continue to HOLD, especially because of their progress in clinical trials. I would probably only buy more if I was diversifying from another biotech (i.e. if DNDN was to climb substantially and soon).DISCLOSURE LTBH since 1999.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar